Beijing Konruns Pharmaceutical Co.,Ltd. (SHA:603590)
29.93
-0.56 (-1.84%)
Sep 2, 2026, 3:00 PM CST
SHA:603590 Revenue
Beijing Konruns Pharmaceutical had revenue of 247.93M CNY in the quarter ending June 30, 2026, a decrease of -0.38%. This brings the company's revenue in the last twelve months to 917.05M, up 4.06% year-over-year. In the year 2025, Beijing Konruns Pharmaceutical had annual revenue of 915.12M with 10.87% growth.
Revenue (ttm)
917.05M
Revenue Growth
+4.06%
P/S Ratio
5.24
Revenue / Employee
1.16M
Employees
793
Market Cap
4.80B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 915.12M | 89.73M | 10.87% |
| Dec 31, 2024 | 825.40M | -94.61M | -10.28% |
| Dec 31, 2023 | 920.01M | 53.29M | 6.15% |
| Dec 31, 2022 | 866.73M | 56.94M | 7.03% |
| Dec 31, 2021 | 809.78M | 1.14M | 0.14% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Anhui Huaheng Biotechnology | 3.00B |
| Wuhan Hvsen Biotechnology | 1.72B |
| Shenzhen Weiguang Biological Products | 1.20B |
| ChemPartner PharmaTech | 1.16B |
| Boji Medical Technology | 961.34M |
| R&G PharmaStudies | 939.31M |
| Beijing Bohui Innovation Biotechnology Group | 816.14M |
| Shanghai Obio Technology (Group) Corp. | 269.63M |